A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the S

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

Abierta

Código protocolo: CLIN-60190-453
Código EudraCT: 2022-002695-37
Grupo de investigación: Enfermedades Hepáticas
Servicio: Hepatología
Investigador/a principal: Campos Varela, Isabel
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase II